These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32406275)

  • 21. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
    Egeberg A; Hawkes JE; Somani N; Burge R; See K; Gallo G; McKean-Matthews M; Gooderham M; Han G; Armstrong A
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):1007-1018. PubMed ID: 38647975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
    Armstrong AW; Puig L; Joshi A; Skup M; Williams D; Li J; Betts KA; Augustin M
    JAMA Dermatol; 2020 Mar; 156(3):258-269. PubMed ID: 32022825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
    Zhang Z; Schmitt J; Wozel G; Kirch W
    Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review.
    Camela E; Ocampo-Garza SS; Cinelli E; Villani A; Fabbrocini G; Megna M
    Dermatol Ther; 2021 Mar; 34(2):e14857. PubMed ID: 33559275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Loos AM; Liu S; Segel C; Ollendorf DA; Pearson SD; Linder JA
    J Am Acad Dermatol; 2018 Jul; 79(1):135-144.e7. PubMed ID: 29438757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
    Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
    J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of erythrodermic psoriasis with biologics: A systematic review.
    Carrasquillo OY; Pabón-Cartagena G; Falto-Aizpurua LA; Santiago-Vázquez M; Cancel-Artau KJ; Arias-Berrios G; Martín-García RF
    J Am Acad Dermatol; 2020 Jul; 83(1):151-158. PubMed ID: 32247872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
    Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
    Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre.
    Fotiadou C; Lazaridou E; Sotiriou E; Kyrgidis A; Apalla Z; Ioannides D
    J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2091-2096. PubMed ID: 27406435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologics for pediatric psoriasis: A systematic review and meta-analysis.
    Sun HY; Phan K; Paller AS; Sebaratnam DF
    Pediatr Dermatol; 2022 Jan; 39(1):42-48. PubMed ID: 34888919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
    Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
    Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
    J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials.
    Elewski B; Rich P; Lain E; Soung J; Lewitt GM; Jacobson A
    J Dermatolog Treat; 2022 Feb; 33(1):261-265. PubMed ID: 32250714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).
    Papp KA; Gerdes S; Leonardi CL; Elmaraghy H; See K; McKean-Matthews M; Konicek BW; Crane HM; Eastman W
    J Drugs Dermatol; 2021 Aug; 20(8):880-887. PubMed ID: 34397207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.
    Egeberg A; Kristensen LE; Puig L; Rich P; Smith SD; Garrelts A; See K; Holzkaemper T; Fotiou K; Schuster C
    J Dermatolog Treat; 2023 Dec; 34(1):2263108. PubMed ID: 37781881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.